Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.
Read transcripts of webcasts and audiocasts
Read transcripts of webcasts and audiocasts
Disclaimer: This is a machine-generated transcript and may contain inaccuracies.
You, and, uh, welcome again to all of you, uh, to this presentation of the Trelleborg interim report for the first quarter of 2024. As we've already stated, speaking, Peter Nilsson, President & CEO of Trelleborg. And also joining me on the call is Fredrik Nilsson, who is the CFO, who will guide us through the financial part of the presentation. And also on the call is Christopher Sharon, our head of investor relations, who is also able to support us if there are any questions which need his support. So, um, using the presentation that we have on our website since a few hours and turning to the first page, which is generally saying Trelleborg interim report, turning to page two, which is the agenda slide, as usual, uh, we split it some highlights from my side and also some comments on the business areas, which is going to be three this time for the first time in some time and then financials, Fredrik is going to guide you through this. And then we finishing up with the summary and some comments on the outlook for the running quarter, and then summing up with the Q&A. And then turning to page three highlights. Uh, we have, let's say the heading improved margin despite slightly lower sales. Uh, sales came in at 8.2 billion, which is let's say down by 5% compared to a year ago, which is then, um. When reflected is 5% down. Reflect organic sales down by minus three. And we also have a negative structural thing here of -2%, which then gets us to this minus five currency. Basically no impact in this quarter. First time since a few quarters. And then of course we now looking at organic sales. Easter holiday, as all of you are aware, has been um was in um. In April last year and in March this year. So that is impacting organic sales by close to 2% in the quarter and primarily then impacting our Sealing Solutions activity. Get back in comment on that. EBITDA ending up at 4090, which is then that's a corresponding to margin of slightly north of 18% and still running restructuring in order to, um, continuously improve structure so that we have, let's say, items affecting comparatives in the quarter of 55 million, also relatively strong cash flow in this quarter. As usual, seasonality means that cash flow in the first quarter is always weaker than the other quarters in the year. But if you compare to a year ago, this is a strong cash flow for Q1, which shows that we've been managing our working capital well, although a little bit muted sales performance. But Fredrik will comment on that as well. And as already told, we are for the first time, uh, let's say also presenting individually Trelleborg Medical Solutions. Get back in comment on that soft start for Medical Solutions in a challenging market. But also I will get back and comment on that when we speak about that business area. We also happy to announce the agreement to acquire Baron Group, which is going to be a game changer for Medical Solutions when we get that into the books. Also to be noted, I mean, beyond the end of the quarter, we finalized the earlier announced M&A acquisition in Korea, which is strengthening us substantially in sales for the semiconductor industry. And we also have signed an agreement to acquire BP-Tech Group, as is called or more used name is called Bolden, which is then a pipe repair business, based in Finland but selling globally. Um, so this is kind of the, the highlights of the quarter. Uh, moving from that over to page four to comment a little bit on organic sales. As you can see, it varies quite a lot across the globe. It is starting with the positive. We have positive growth in Asia driven by strong development in China where we see a good bounce back, continued good bounce back, good order intake, and overall good development, but once again driven primarily by China. Europe is flattish with a kind of mixed development between countries and markets. But the summing up led to no growth at all in the quarter. And then we have a substantial negative growth in North America, driven by some inventory focus, but also some. And kind of challenging markets, mainly in the construction and highway-related activity, which is primarily linked to our hydraulic and pneumatic sales, used in areas like construction equipment, agriculture, and also partly mining. So, that is kind of the explanation of this fairly heavy negative in North America. Turning back to page five. Let's move to business areas, quickly to page six and comment on Industrial Solutions. Heading: Improved Profitability Despite Lower Sales. Organic sales down by 3%, M&A supported by 1%. It should be noted that this is in relation to a fairly strong quarter a year ago. It's basically the same development that we see in the last few quarters here, where we see residential construction and certain industrial segments. The Industrial segment, which is mainly exposed to distribution, continues to be soft. We see that the overall product-related sales and solutions continue to perform well. And we especially note that the liquefied natural gas customers are increasing orders and sales substantially, which is kind of assisting us. And also, we note that automotive sales are still growing in the quarter. I mean, we are watching this carefully, but at the moment, we still see good automotive sales in this business area. Overall, well managed. I mean, we continue to benefit from structural improvements, good price management, and also a positive sales mix, which is then pushing the margin to high levels for this business area. And also, as already commented, we continue to build on our business for pipe repair, bolstered by this acquisition, and that continues as a prioritized area for us where we hopefully can continue to build an even better position in this attractive and rapidly growing segment of pipe repair or relining of water pipes. Turning to page seven and commenting on the new business area, Medical Solutions, a fairly muted start. Impacted by inventory adjustments in the industry? We have some heavy as bigger customers, which are, let's say, undergoing heavy inventory reductions in the quarter. The underlying demand is still okay. And that is why, although we know that this is soft, organic sales. And we are also guiding for soft organic sales. In the next quarter and the current quarter. We still feel that the underlying demand is good and that overall we will see a fairly flattish development, actually for the full year in medical solutions in relation to organic sales development. EBITA margin is improving, and we are therefore able to, despite a fairly dramatic sales drop, still manage to deliver an EBITA in line with last year and actually with an improved margin. And we also continue to talk about Baron Group, which we believe will be, let's say, closed. This deal will be closed within the current quarter. We don't know exactly when, but within the current quarter, we expect that to be closed. And when that gets in, we know that we will have synergies and we will also have a substantially better overall performance of Medical Solutions. We are also going to continue to develop this new business area structure, and we're adding resources in order to be able to approach all the interesting customers and all the interesting segments. And this is also something that we, as before, want to note that we're running with a slightly higher overall cost level in the business areas in order to position ourselves in the best possible way for the future. And turning to page eight and commenting on Sealing Solutions organic sales as a minus two, which is, let's say, due to the. Yeah, the lion's share impacted by the placement of Easter this year. Um, so let's say if we allow ourselves to adjust for that, as you know, it's a flattish sales in the quarter. Sales to the general industry are the ones being pushed down, where we are seeing, or being told by our customers, that this is mainly related to continued inventory focus and not really to a lower overall demand. Automotive demand in this business area is flat, with really no change from a year ago. And we continue to see very strong sales development in aerospace, good order intake, and also good sales development in the quarter. EBITDA and margin are down, primarily related to earlier acquisitions still being integrated and in a good way. But the benefits will. Kicking in, as we said before, here during later this year and also going into 2025, but of course also impacted by these slightly lower volumes as we are on top of this, also focusing on our inventory, we are not, let's say, overproducing. We're actually more or less underproducing in the quarter in order to make sure that we protect the cash flow. And that is not to say, building inventory in any way. Um, also in this area, like in medical, we continue to invest in what we call soft growing market segments like semiconductor and aerospace, where we are still running ahead a little bit with our resources in relation to the sales. But where we see that it is going to have a positive impact in the medium to long term. For the business area. So this is really what we're going to say about the business area at this stage. And moving on, a few comments on our sustainability KPIs, with the focus on carbon dioxide, continue to develop very favorably for us. We are successful in lowering our emissions, as you can see on the slide, and especially also if you are primarily driven, if you turn to page ten, with the continued increase in the share of renewable electricity, we feel that we are very well on the way to developing our targets in relation to CO2, but more of that in the future. And turning then to page 11 and the agenda slide and the financials, and then leaving it to Fredrik to guide you through starting with page 12. Thank you, Peter. Starting with the sales development for the quarter. As Peter Nilsson mentioned, organic sales dropped by 3% in the first quarter. Industrial Solutions declined by 3%. Medical Solutions and Sealing Solutions were down 2%. And then, as you can see on the slide report, net sales decreased by 5%. And I said 2% minus from structure, which is mainly related to the divested business in the Czech Republic during autumn 2023. Moving on to page 13.
Showing the historical organic growth. As you can see here, the first quarter was below our sales growth target, which is 8% over a business cycle. Moving on to page 14, showing the quarterly sales over 12 months for continuing operations. The sales in the quarter reached 8.2 billion, and over the rolling 12 months, it reached 33.8 billion SEK. Moving on to page 15. Looking at the EBITA and EBITA margin development, EBITA, excluding items affecting comparability, decreased by 2% to 1,490 million. With profit growth in Industrial Solutions, a flat development in Medical Solutions, while it declined in Sealing Solutions. In the result, there was a small translation impact, which was negative of 14 million compared to the corresponding quarter last year, margin-wise, up 0.6 percentage points from 17.5% to 18.1%. And that is despite that we initially have some acquisitions with lower margin. And that's also, as Peter Nilsson was mentioning, we have invested in the organization in some fast-growing market segments. Moving on to page 16. Looking at the rolling 12 months EBITA. It amounted to 5,964 million, with a margin of 17.6%. That implies that we have had an EBITA growth of 7% during the last 12 months. Going into some more details on page 17 in the income statement. We have items affecting comparability in the quarter of 55 million, which is entirely related to restructuring costs. Due to that, we are adjusting our cost base. I would also like to highlight our financial net. That is down from 165 million negative to -20 million, and that is mainly due to that. We are now in a net cash position, but also that in the corresponding period last year, we had a short-term loan for financing the Minnesota Rubber and Plastics acquisition that was repaid during the second quarter of 2023, when we received the proceeds from the wheel systems divestment. Tax rate for the quarter is 25%, which is fully in line with earlier guidance. Moving on to page 18. Looking at earnings per share, a strong improvement of 16% for earnings per share, excluding items affecting comparability, and that is due to the improved financial net, but also due to the ongoing share buyback program that we have fewer shares when we calculate earnings per share. If we look at the total group, you can see it's down 24%. But that is explained by the discontinued operation related to wheel systems and printing blankets that was divested in May 2023 and that added to discontinued operations added 1.816 to the EPS. Page 19. Cash flow. A good improvement compared to 2023. As you can see, working capital an improvement of 150 million and also slightly less CapEx in the quarter. Looking at page 20, the cash conversion remains at a really good level and reached 95% on a rolling 12-month basis. Looking at gearing and leverage. I would like to highlight here that as we are still in a net cash position, the reported net debt ratio should become negative and amount to minus two. And if you look at net debt or net cash in relation to EBITDA, it was minus 0.1. And we have also bought back our own shares for 1,085 million in the first quarter. Return on capital employed on page 22. Excluding items affecting comparability was 12.7% compared to 14.9% a year ago, and that is due to the acquisitions with initially lower returns and also the small, lower profit that we have this year. Looking at page 23, some guidance for the full year 2024. They are unchanged compared to what was presented in February. So CapEx is still 1.6 billion, restructuring costs of 250 million for the full year, amortization of intangibles 500 million, and the underlying tax rate remained unchanged at 25%. So with that, I would like to hand back the microphone to you, Peter.
Thank you. And turning to page 24 of the agenda slide, then quickly to page 25 to give you a summary. Again, I mean improved margin despite slightly lower sales. And we feel the quarter is well managed. I mean, we still had these negative organic sales primarily driven by inventory reductions. And not really, let's say, a firm indication of any kind of lower demand. We still, as usual, have a mixed picture. I mean, we will see a few segments doing very well. We already mentioned LNG, oil and gas, aerospace. Um, we also have semiconductors performing well. And we do also see kind of a good underlying demand in the medical area, although we are heavily impacted by inventory adjustments for some of our key customers. So, overall, a solid quarter. We feel impacted, of course, by the Easter holiday. Already commented a few times, strong cash flow in the quarter, let's say, in relation to the season. I mean, we feel satisfied with the management of working capital, well done by our units to manage this in the quarter. And we also noted satisfaction that we are adding to our medical business with this Baron Group acquisition. Now, we are eagerly looking forward to closing that deal and integrating it to get the synergies that we identified in order to push and improve the medical solution substantially following this integration. And we also see this, call it smaller but very interesting, moves, needless to say, on M&A in Korea, which is offering a new platform for us in Asia for sales into the semiconductor manufacturing industry. And we also noted satisfaction. Another interesting and very nice add-on for us related to the pipe repair aftermarket for water and wastewater infrastructure. So I mean, a good quarter, a lot of things moving in the right direction. We continue to have our focus on delivering on our margin target, 20% plus. And we feel that this quarter is a step in the right direction. I mean, we are able to increase the margin, although we have a decrease in organic sales. And we feel when this is normalized and we see, let's say, a little bit of growth potentially, then we feel confident that this extra growth will deliver a good leverage. And we will then get closer to our target of 20% plus EBITA, turning then to page 26 and commenting about the outlook. We don't really see any changes. I mean, the order book is solid in a way we don't see as a decline in the order books. We see overall good development. But we are, of course, fully aware of this uncertainty where we see, unfortunately, around the world with the continued conflict in Ukraine and also with this, um. Or should I say, uncertainty in the Middle East, which of course could impact us. And we also see a continued focus on inventory reduction, which is for some of our customer segments. Um, but with that said, we still have, once again, a solid order intake, which does not really indicate any. And the kind of dramatic changes. But once again, this outlook is, of course, let's say, linked a little bit to, to bigger uncertainty than usual. But overall, looking into what we know from before and what we see in our businesses, we feel that there's going to be. Equal development in Q2. As we said in Q1. And with that, turning to page 27 and quickly to page 28 and opening up for a Q&A session. So please, go ahead.
If you wish to ask a question, please dial Pound Key five on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial Pound Key six on your telephone keypad. The next question comes from Eric Gaughran from SEB. Please go ahead.
Thank you. I have a couple of questions. First, on the demand side for the second quarter here, a two percentage point drag from Easter. How you talked about the generally stable demand trend. And then you have this destocking element in medical, which is a bit uncertain about the near-term. But there must have been an alternative to guide for sort of higher growth, given the swing in seasonality and no other real sort of underlying factor changing much. That's fair to assume.
Yeah. Having a quick comment on that. I mean, we are of course, if we look solely at the order book, it would be better in Q2. But we also note that there is, uh, uncertainty. And we want to be a little bit more on the cautious side. If you if we may say, I mean, we are still trying to make sure that we don't overproduce and that we don't really, um. You believe in a brighter future. And then we see. But of course, I mean, you are right in that way that, I mean the Easter effect will be positive in Q2 and it was negative in Q1. So you could I could agree with you that we are a little bit on the careful side, but nevertheless, I think when we put everything in the bag and we look at it, then we believe this is a fair, um, a fair comment and fair assumption that we're going to see a similar development in Q2 as we saw in Q1. Okay, thanks. Then to highlight on this also, Eric, I mean, the order book is solid. I mean, there now is this how much we continue the inventory focus we have. We still see that some of our core industrial customers are. Uh, they're trying to get their inventory down, although they continue to place orders. So this is the kind of development we've seen for a few quarters. And I think I've commented to you before as well. I mean, we wouldn't be surprised about that. And there is nothing that is coming. So, if that kind of trend is changing, then of course, we will see. Uh, a more positive sales development.
Okay. Understood. And then two questions on profitability. First one in medical, when Baron comes in, it will do 20% EBITDA. I guess that implies Baron is doing 30% or so, which is a very high level. Any reason to feel that's not a sustainable level for them, or what's the main factor putting them at such a high margin? And then second, on the industrial side, you've been a bit more inclined towards expectations of a more sideways margin development for industrial after a really strong 2023. Now, this first quarter, we're up again. Have you been too cautious on mix or price here? What's the delta? Thank you.
No, it's the first year for medical. I mean, we fully understand that there is a big difference between the 14% in this quarter and the 20% that we guided for going forward. We feel confident we have an operating plan. We know what we want to do with Baron, and we know what benefits we will get with Baron. So, we fully understand that the proof is in the pudding there, and we have that to deliver. But we still want to comment on, I mean, that is the long term. A long term. The medium term, even short term target area is to get medical up to 20%. And that is what we are still aiming for. And I mean, I understand that you are in doubt, but that is something that we are working towards and something that we believe in. And we need to prove that it is happening. With industrial, it was a bit of a positive mix in the quarter. We said we had some product sales, especially related to liquid natural gas segments, but also a little bit extra volumes in automotive, which created some extra well, that we know not on the most profitable part of the business area, but nevertheless, we benefited from that. So there is a bit of a negative mix in the current quarter in the last Q1. And we do not fully expect that to continue in the same way. But we still feel that overall, the business area is moving in the right direction. And I think the overall guidance is still valid. That we believe is to increase by half a percentage point per year. And we also saw a comment on that. It will vary, let's say, between the quarters. And this was probably a little bit on the high side in this quarter. And of course, we will try to continue to deliver in the same way. But I mean, it was a little bit on the high side. I don't know if Fredrik, if you want to supplement anything on this.
I think we also flagged already last year that we have some product releases both in Q2 and Q3. Last year we managed to improve the margin a little bit. So I would say we have a bit tougher comparisons as well going into Q2, Q3.
Very good. Thank you.
The next question comes from Klaas Berge, on the line from Citi. Please go ahead.
Thank you. Hi, Peter and Fredrik. Klaus. So, coming back to this destocking, I almost lost count. I think this is the third quarter with this destocking in North America. It's obviously highly unusual. We had this massive pre-ordering effect, etc. And I mean, we expected that. But when you look ahead, Peter, and look at the inventories among your customers, speaking to your customers also in the channel, are you getting any indication that we're coming to an end? You gave a very specific comment on the destocking in medical, but I'm curious to hear what you're hearing on the industrial and construction verticals. Thank you.
Yeah. No, I think we are also surprised, to be honest. I mean, I think it's actually the fourth quarter that we see this kind of destocking effect where there is kind of ordering. Or not ordering. Order intake is actually good. It's positive in the quarter. But they still continue to do the call offs on a lower level. And I mean it's difficult for us as well, to be honest. I mean, we don't really follow it. We get guidance from the customers that the destocking is ending, but then they still continue to order below. And I don't know where it goes to that they are expecting, speculating on lower pricing, or that they are even more cautious. What we'll be highlighting in this specific quarter is more related to off-highway, which is kind of where we see an increased destocking in the areas of construction equipment and mining a little bit, and also agriculture. So these are the areas which have been, let's say, more impacted in the quarter. And we continue to see kind of a lull also, which we have had for some time. Also, less and more residential construction is also continuing on a downward trend. We are also, to be honest, a little bit surprised that this is continuing and we don't really see customers indicating lower demand. They are indicating that they are more cautious. So that is something we are watching carefully and something that we are aware of. Uh. Yeah. Aware of that. This is strange. I mean, historically, if we go back to earlier cycles, this destocking has only been for two quarters. So now we're at the fourth quarter. So it is a surprise to us and I don't know what to say more. Oh no no.
No no, I appreciate the difficulty. And my second question, um, I get Frederick's answer on this that obviously there was a little bit of an anomaly to have it at these high levels, but, um, coming to the margin in, in pts, better margin than I thought, despite the Easter effect. And when we get this calendar effect, obviously there is more under-absorption which is set to reverse into the second quarter. And given that you say that the MRP integration is on track, I'm just wondering if we can get closer to almost 22% once this Easter effect reverses. I know that the 23% target is more towards mid-2025, but the margin was better than I thought despite the negative volume. So I'm curious about the Easter impact if you can quantify it.
Thank you. But we are not guiding specifically on the margin for an individual quarter, to clarify. But what we meant with the MRP integration, and we have clearly also said all the way that it's tech-heavy. So most of the synergies will materialize in 2025. But we are seeing progress with the products that we are running. That's how you should read that comment.
But we are of course running with low capacity utilization. We are running with low capacity; we are underproducing actually in the quarter. So of course, if there is, let's say a positive volume impact, we. If we manage that well, there should be a good drop-through. But we are not confident to say that this kind of volume, extra volume, is kicking in already in Q2. But when it comes, we do expect a substantial leverage on that extra volume.
Yes, but it is almost mathematically certain that you get 2% back. But that was my point. And my point as well was that I totally get the whole comment. You don't guide, you know, per quarter. But I think it was still an encouraging level given that you're still in the early days of the M&A and then Easter reverses. I guess that was my point, but. Thank you.
Thank you.
The next question comes from Timothy Lee from Barclays. Please go ahead.
Hi, Peter.
Hi, Fredrik. First of all, thank you for taking my questions. The first question is about China. So you mentioned that China is the key driver for recovery. Can you elaborate a bit more about from what segments you see the strength to come from? And whether it will be something that you see to be sustainable momentum, given that when we look at the commentaries from other companies with high exposure in China, they are actually giving quite a mixed picture. Regarding the recovery in China. So I'd like to hear what you are hearing from the ground about China. That's the first question. And the second question is a little bit more on the margin. So again, it is quite good development in the margin. Can we say that the impact from the previous investment in the key fast-growing segments is behind us so that we would see some more improvement in terms of the segment margin, even though the synergies coming from the acquisitions mainly come in next year rather than this year?
And on China, I think it's a fairly wide improvement. We do not see improvement. If you say residential construction, we are not that exposed to it. But just to clarify, it is not coming from that. Where we still see, on the limited exposure we have to that segment, we still see a downward trend. But we have, let's say, overall, infrastructure construction is doing well. Also, this relates to mining and construction equipment for infrastructure construction, which is performing better, though from fairly depressed levels. To be honest, there is not really a return to where we were before, but nevertheless, there is a strong uptick. Semiconductors is another area which is doing well for us. We also see the industry is generally improving. So, it's a fairly wide improvement. But also, we need to be aware that it's coming from a fairly low level. So, there are very easy comps. So we must not overreact to it or make it, let's say, too big of a thing. But nevertheless, it is a substantial improvement compared to a year ago. Indeed, there was an industrial solution. So was more, I don't know if you can take that.
I understood it was Sealing Solutions. I mean, the investment organization and the payoff of those investments.
Yeah, exactly.
Yeah.
And I mean, that will come gradually. We have invested in the organization. I mean, we're talking about aerospace, health, and what in the past was medical, now is Medical Solutions to America and a few other segments. And then, of course, that should turn into incremental sales. So that will come gradually during the year and in the coming years. We will.
See, let's say, in.
Aerospace.
Firm payback in volumes. I mean, honestly, they're struggling with growth a little bit there. So, we don't really get the efficiency we want in aerospace. So, there we also need some operational improvements. So, that is kind of an investment. So, it's paying off in terms of extra sales. But I mean, we should get a better margin out of that. This is simply to be very blunt about that. Semiconductors are also kicking in. I mean, it's a smallish area for us, but nevertheless not without many investments. And with this, how should I say, the desire from some of the Asian users of semiconductor equipment to get away from American supply. We are benefiting from that. So, that is also something which is resulting in very strong order intake, but also on that one, we are a bit struggling to get full efficiency out of that growth yet. But nevertheless, very positive. So there are several areas. Electrification is another area where we have a lot of small businesses. It's not about big orders but a lot of small pockets, which are growing. We are launching a new food-grade material as well, which is also picking up. I mean, as you know, there is this discussion on PFAS, no previous material. And when we have, let's say, a very good position in the areas where PFAS is going to be replaced. We have a very good portfolio of materials also, as we see good order intake. So, in general, I think the efforts that we are making are paying off. But as we commented before, it will take time to get it into the factories and achieve full efficiency and get it into the profit at the right levels. But overall, we are satisfied. And then, of course, there are a few areas which are lower, like hydrogen or something like that, which is more very early days. But overall. We feel the water segment is also an area, but just to note a few, which is still slow, which is impacted by residential construction being low. But we also see that as we move forward, we have a good. Good range of materials being launched into that area, but we still don't have the optics. So even though we are kind of exposed to depressed sales, we are still investing in those segments because we believe in them long term. So it's a mixed bag. But we think it's, we firmly believe that we're doing the right thing and that we are going to get the full benefits. That is eventually.
Cool. Very helpful. Thank you so much.
The next question comes from Hampus Angulo from Handelsbanken. Please go ahead.
Questions for me. My first question is related to Baron, and it would be interesting to know when you were doing your due diligence on Baron, if they had any significant impact on sales and earnings from COVID-19. That's my first question. The second question is related to the market. I think that.
Immediately, I mean, they are not exposed to COVID in the same way. So, they are exposed to other segments where we are not really being fully transparent yet about which segments. But, they are not exposed to the COVID segment like that.
So, for next, if more is more, more like your sense for underlying activity in the market. We heard some other consumer goods companies reporting on improving demand in early cyclicals. We heard something from somebody talking about their business. We heard about AB and also some positive signs in Europe. It would be interesting to hear your take on that. Given that you had earlier mentioned being a bit cautious on your guidance. So, I guess I'm coming back to that. Thanks.
You know, that's what I mean. We see order intake is better than sales if I put it like that. So, we are all moving in the right direction. But generally, if we say especially in sealing solutions, if we get orders there, it's a 3 to 6 months ahead of us before we see the sales, whereas there is a specific look at the order book. It's going to get better. But of course, then we still have this uncertainty on inventory and the geopolitical situation overall, which could, let's say, create. So, some extra cautiousness among a few of our customers. But, I mean, it is we see the same. And if you refer to that, we see the same that this is slowly improved. Demand in the order book is growing, but sales are not growing at the same. Speed as the sales are not growing at the same speed as the order book is improving.
Fair enough. Thank you very much.
The next question comes from Douglas Lindell from DNB Markets. Please go ahead.
Hello, gentlemen. I only had one question, actually. And circling back to the Baron acquisition, given the importance that this company brings in terms of positive margin contribution, I would be curious to hear if you have any sort of updates on when more specifically, we can expect this to be finalized. Obviously, you said before H1, but if you have any sort of updates, it would be hugely interesting to hear.
Yeah, I mean, we are moving forward on that, and we have more or less all approvals in place. We're waiting for some formal approvals. Um, and that is kind of because the indication is that it will be closed, let's say, well, within this quarter, let's put it like that. But there is still uncertainty since we're waiting for some, uh. Tom, how should we put this, as a formal approval where we cannot control? So, everything which is, uh, under our management, our control is in place, and we are still waiting once again for some formal approvals. Uh, the indication is that we're going to get it in the next. Four weeks. Put it like that. But once again. And then, of course, it relates to the clause, as you know. Then we need to close it at the month-end or a minimum of something like that. So, we are curiously looking at exactly the date when we're going to get to it. If, if you then, uh, yeah. Yeah, but I get to play comfortably with the more.
Okay. No, that's, uh. That's good. Thanks so much.
The next question comes from Agnieszka Villella from Nordica. Please go ahead.
Perfect. Thank you. I missed the beginning of the call, so apologies if my question has been asked, but on medical solutions, do you expect to reach a 20% margin after the Baron integration. But you can see that so far the business has been running at about a 15% margin. And with Baron adding 30% to sales to the division, it needs to run at a significantly higher margin. So my question really is if you did quantify the exact EBITDA margin that Baron is doing right now.
Uh, we are not yet the owners, and we don't really want to comment on that, but we understand that this is, um, looking ambitious, but we have a firm plan on how to get there with synergies with the integration of Baron and with also the kind of operational improvements in the running business as a combination of a few things. Uh, but, uh, that is a challenge, uh, that we have taken on and which we believe that we will conquer and that we will get to these 20%, uh, fully understanding. Yes, there are some doubts on exactly how to get there, but that is, uh, yeah, the proof is in the pudding there. And we believe that we're going to show you, as a, uh, by the end of this year, that we're going to get to this, uh, running rate of 20.
Perfect.
I don't care if I can comment anymore on that one because there are some synergies related to this as well, which have not yet been, uh, communicated.
Understood. And then on the destocking, the division. Um, when did it start really? And when they're expected to finish.
It will be fairly late. I mean, I don't know, of course, we know we're a little bit. But if you look at our competitors, they were kind of exposed to this already. I think two quarters ago, we saw two quarters. That was the first one, I would.
Say, probably during the autumn of last year. Yeah, and through the winter. So, we haven't had any impact until very recently.
Basically, we've been holding up, call it, some product sales or some special sales within medical. And since they are dropping away now, we are fully exposed to these inventory drops. I think we've been overperforming, if I may say, for one or two quarters longer than most of our competitors. And this is now hitting us in this quarter. Um, and we are not, um. Surprised, in a way, if I may say, we knew that it was coming. And there are a few individual cases, which are impacting us quite a lot. So, it's not kind of an overall drop of 10%. It's more linked to individual cases, which then hit us a little bit harder. Um, but, of course, I mean, that is, I guess, I don't know, Christopher, you are looking into this a lot as well. Yeah, well.
To answer your question, we see the same development year in, year out in Q2, and then we see an. Improvement. Substantial improvement, substantial improvement in the second half.
The underlying order book is good. I mean, the new product inflow is good. That is, the new call of the new projects is good. But this is more or less about running sizable customers that we have, which has indicated that they will not order anything before going into the second part of the year. So, that is kind of the impact that we see.
Great. Thank you. And then my last question is on your capital allocation. What priorities do you have during 2024?
No, no, I mean, it's the same as before. We're going to continue to invest at a fairly high level. We are improving our geographical balance. But by, you know, we are. Creating new capacity in India. We're building two new factories in Vietnam and expanding in China. And at the same time, of course, also improving our footprint in Europe and improving our footprint in North America. So, we are going to continue to run CapEx in a good way. And now, also with Baron, with Trelleborg Medical Solutions, we will also be adding a plant in Costa Rica. So CapEx is going to be high. Continuing on a relatively high level from, for instance, historical norms for us with regards to acquisitions, we are still scouting for acquisitions. We are targeting primarily bolt-on acquisitions. Once again, we've been committing to this Baron acquisition, which is kind of a platform acquisition for us, which is different than the others. So, hopefully, you will continue to see bolt-on acquisitions, which are highly synergistic for us. And we're doing that, as I said before, with the focus on these speedboat segments and, let's say, very close to the core of existing business in a way. So we are not looking for any new areas outside of our current scope. Uh, but we do spend some time we have we then intensify the actions in order to, um. Hoping to kind of get a few of these cases executed. Also to note that we still feel that kind of valuation is still. Quite attractive. Of course, there is always competition and acquisitions, but we don't really see the competition increasing at the moment. So, we try to get the ones done which are available and suit us. So, you're going to see us investing heavily in capital and CapEx. And you're also going to continue to see us making acquisitions. I mean, once again, with this kind of size, don't expect that to happen. It's going to be smaller acquisitions in the future. Yes, what you say is tens of millions of euros. I mean, that is really the size that we are primarily looking at at the moment.
Yeah.
And lastly, on share buybacks, is there any limit that you are setting yourself on repurchases?
No. Let me continue on the same. And we have the AGM here in an hour or two. And we're going to ask for a new mandate to continue in the same way for another year. Which is, so the run rate is then going to continue to be a billion in the second quarter, roughly. Um, so there's no change in that one. We feel that we can manage this pace of buyback. While still maintaining, let's say, a strong balance sheet, and still having cash to execute both the increased CapEx levels and also to continue to execute on these, if I may call them, smaller bolt-on acquisitions.
Perfect. Thank you, Peter.
There are no more questions at this time, so I hand the conference back to the speakers for any closing comments.
Okay. Thank you. Thanks to all of you for showing interest in Trelleborg. And as usual, Christopher is well, very prepared to support you further with any other questions. And Fredrik and myself will be on roadshows in the next few days. So, some of you will probably meet us, and if you want to meet us then please make contact. And we are eager to support you to get a better grip of the global story. So, thanks again. And um, talk to you or speak to you soon again.



















